Eleonora Bellissimi

Jun 23, 2023 | bioprocessonline.com | Erika Roberts |Ian Brown |Eleonora Bellissimi |Hue Rose Pham

By Erika L. Roberts, ELR Lab Services LLC Aptamers offer advantages over antibodies, including lower immunogenicity and toxicity, better tissue penetration, lower production costs, and a long shelf life. Why, then, have we not seen more of these come to market? Two hurdles have stood in the way until recently.

Jun 9, 2023 | pharmaceuticalonline.com | Ambreén Zaman Riaz |Uppshot Lifesciences |Kelly Stewart |Eleonora Bellissimi

By Ambreén Zaman Riaz, MBBS, MPA, Uppshot Lifesciences The advancements in artificial intelligence and machine learning algorithms means we can use large pools of genetic data to identify potential risk factors and disease-causing genes for multiple sclerosis and other autoimmune diseases. This author shares a three-pronged approach to analyzing data for AI algorithms, pitfalls to avoid, and AI for silico modeling.